Abbott announces CE Mark and first use of the world's first smartphone compatible insertable cardiac monitor

Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will help physicians identify difficult to detect cardiac arrhythmias, including atrial fibrillation (AF), to help guide therapy. Since CE Mark approval, adoption of the device has been strong and implants have occurred in 10 countries across Europe.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Abbott Business and Industry Source Type: news